Agile Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Agile Therapeutics

11/05/2023 22:01

* Agile Therapeutics Inc  AGRX.OQ  reported a quarterly
adjusted
loss of $5.91​​ per share for the quarter ended in March. The
lone analyst forecast for the quarter was for a loss of $7.50
per share.
    * Revenue rose 116.5% to $3.81 million from a year ago;
analysts
expected $3.40 million. 
    * Agile Therapeutics Inc's reported EPS for the quarter was
a loss
of $5.91​.
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Agile Therapeutics Inc shares had fallen by 47.8% this
quarter and lost 48.5% so far this year.
    * The company reported a quarterly loss of $5.39 million.
    * Wall Street's median 12-month price target for Agile
Therapeutics Inc is $250.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -7.50          -5.91          Beat
 Dec. 31 2022      -11.50         -5.00          Beat
 Sep. 30 2022      -22.00         -26.50         Missed
 Jun. 30 2022      -1.85 hundred  -1.35 hundred  Beat